Approved Immune Checkpoint Inhibitors in China: PD-1, PD-L1, CTLA-4 and Bispecific Antibodies
Immune checkpoint inhibitors (ICIs) restore T-cell–mediated antitumor immunity by blocking key regulatory pathways such as…
Articles
Belantamab Mafodotin Approved in China for Multiple Myeloma: First-in-Class BCMA ADC Marks New Milestone
On April 17, China’s National Medical Products Administration (NMPA) approved belantamab mafodotin in combination with…
Top 5 Global Neuroscience Pharma Companies: Core Products and Pipeline Analysis
Neuroscience (CNS) has long been regarded as one of the most challenging areas in the…
Sevabertinib Approved in China for HER2-Mutant NSCLC: A New Oral Targeted Therapy Option
On April 15, Bayer announced that its innovative targeted therapy Hyrnuo® (sevabertinib, BAY 2927088) has…
HCC First- and Second-Line Treatment Updates: What’s New in Current Guidelines
To further improve the standardization of diagnosis and treatment for primary liver cancer, the newly…
What Are the Top 5 Autoimmune Diseases to Watch in 2026? Insights into Immunotherapy Trends and Innovation
Over the past decade, autoimmune diseases have remained one of the most stable and high-growth…
China Pharmaceutical Export Trends and Global Pharmaceutical Market Opportunities
China’s pharmaceutical industry is undergoing a profound structural transformation, and China pharmaceutical export trends are…
Bispecific ADC Development in Breast Cancer: Emerging Targets and Clinical Progress
Breast cancer is the most common malignancy among women worldwide, with incidence continuing to rise.…
Approved Cell and Gene Therapy Drugs in China and Key Differences Between Cell Therapy and Gene Therapy
The landscape of approved cell and gene therapy drugs in China is rapidly evolving, as…
NMPA Approves GSK Depemokimab in China for Severe Eosinophilic Asthma with Twice-Yearly Dosing
On March 27, 2026, the National Medical Products Administration (NMPA) of China officially approved GSK…